Clinical Trials for Ovarian Cancer

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable, platinum-resistant high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer, ECOG 0–1, and 1–3 prior treatment lines receive raludotatug deruxtecan, a CDH6-directed antibody–drug conjugate that delivers a topoisomerase I inhibitor. The study first evaluates three doses, then compares the selected dose with investigator’s choice of paclitaxel, pegylated liposomal doxorubicin, gemcitabine, or topotecan.

ClinicalTrials.gov ID: NCT06161025

FRAmework-01: A Two-Part Phase 3 Study of LY4170156 Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with progressing high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are enrolled in separate platinum-resistant and platinum-sensitive cohorts. The platinum-resistant cohort compares LY4170156, a folate receptor alpha–targeting antibody–drug conjugate that delivers the topoisomerase-I inhibitor exatecan, with chemotherapy or mirvetuximab soravtansine; the platinum-sensitive cohort compares LY4170156 plus bevacizumab with carboplatin-based chemotherapy plus bevacizumab.

ClinicalTrials.gov ID: NCT07213804

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that has progressed after platinum therapy and 1–3 prior systemic treatment lines are assigned to FRα-high or FRα-low cohorts. Both cohorts compare AZD5335, an investigational FRα-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, against mirvetuximab soravtansine in FRα-high disease or investigator’s choice of paclitaxel, pegylated liposomal doxorubicin, or topotecan in FRα-low disease.

ClinicalTrials.gov ID: NCT07218809

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls patients with measurable, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer with cyclin E1 overexpression after 1–4 prior systemic therapy lines; primary platinum-refractory disease is excluded. Patients receive investigational oral INCB123667, a CDK2 inhibitor, or investigator-selected single-agent chemotherapy.

ClinicalTrials.gov ID: NCT07214779

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Patients with recurrent platinum-sensitive high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer who have complete response, partial response, or stable disease after second-line platinum chemotherapy are randomized to maintenance rinatabart sesutecan plus standard of care or standard of care alone. Rinatabart sesutecan is a folate receptor alpha–targeting antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan; standard of care is bevacizumab maintenance or observation.

ClinicalTrials.gov ID: NCT07225270

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Women with measurable, cyclin E1 protein–positive, platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer and 1–3 prior treatment regimens (up to 4 after mirvetuximab) are randomized to oral azenosertib, a WEE1 checkpoint kinase inhibitor, or investigator’s choice of chemotherapy. Primary platinum-refractory disease is excluded.

ClinicalTrials.gov ID: NCT07546500

A Phase 2 Non-comparative Screening Trial of Sacituzumab Tirumotecan (MK2870) Alone and in Combination With Pembrolizumab in Ovarian Clear Cell Carcinoma Previously Exposed to Immunotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with relapsed pure ovarian, fallopian tube, peritoneal, or endometriosis-associated clear cell carcinoma after platinum/taxane chemotherapy and exactly one prior immune checkpoint inhibitor–containing line receive sacituzumab tirumotecan alone or with pembrolizumab. Sacituzumab tirumotecan is a TROP2-directed antibody-drug conjugate delivering a topoisomerase I inhibitor; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT07718854

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For patients with measurable, platinum-sensitive recurrent high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer after first-line carboplatin/paclitaxel, this study compares second-line rinatabart sesutecan (Rina-S), with or without bevacizumab, against investigator-selected platinum-based chemotherapy, with or without bevacizumab. Rina-S is a folate receptor alpha–targeted antibody-drug conjugate that delivers a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT07564141

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive recurrent or metastatic solid tumors across 13 cohorts receive intravenous ifinatamab deruxtecan, generally every 3 weeks. This investigational antibody–drug conjugate targets B7-H3 (CD276) and delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06330064

Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with measurable metastatic colorectal, pancreatic, biliary, gastroesophageal, urothelial, ovarian, or nonsquamous non-small cell lung cancer that is refractory to or intolerant of standard treatment receive devimistat, an investigational inhibitor of mitochondrial pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes. It is combined with hydroxychloroquine and 5-fluorouracil for colorectal, pancreatic, and gastroesophageal cancers, or with gemcitabine and hydroxychloroquine for urothelial, ovarian, and lung cancers; the biliary regimen is described as devimistat with gemcitabine or hydroxychloroquine.

ClinicalTrials.gov ID: NCT05733000